Home › Hypertrophic Cardiomyopathy › California › San Francisco
Hypertrophic Cardiomyopathy clinical trials in San Francisco, CA
4 studies for Hypertrophic Cardiomyopathy are looking for participants at sites in and around San Francisco (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
RecruitingObservational study
- University Of California San Francisco Medical Center, San Francisco
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
RecruitingPhase 2
- Imbria Investigational Site, San Francisco
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
RecruitingPhase 1/2
- University of California San Francisco, San Francisco
Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy
Recruiting
- University of California - San Francisco, San Francisco
Hypertrophic Cardiomyopathy trials in other cities
- Boston, MA6 studies
- Cleveland, OH4 studies
- Charlottesville, VA4 studies
- Chicago, IL3 studies
- New York City, NY3 studies
- Plano, TX3 studies
- Charlotte, NC3 studies
- Houston, TX3 studies
- San Diego, CA3 studies
Other studies in San Francisco
- Prostate Cancer45 studies
- Breast Cancer43 studies
- Non-Small Cell Lung Cancer36 studies
- Cancer (all types)35 studies
- Heart Failure29 studies
- Metastatic Cancer28 studies
- Lung Cancer22 studies
- Melanoma22 studies
- Pancreatic Cancer20 studies
- Ovarian Cancer19 studies
- Colorectal Cancer18 studies
- Cardiovascular Disease18 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.